News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
340,718 Results
Type
Article (20763)
Company Profile (140)
Press Release (319802)
Multimedia
Podcasts (94)
Webinars (16)
Section
Business (105789)
Career Advice (889)
Deals (18608)
Drug Delivery (100)
Drug Development (51034)
Employer Resources (80)
FDA (7793)
Job Trends (7813)
News (186704)
Policy (17473)
Tag
Academia (742)
Accelerated approval (10)
Adcomms (22)
Allergies (65)
Alliances (27997)
ALS (72)
Alzheimer's disease (729)
Antibody-drug conjugate (ADC) (129)
Approvals (7863)
Artificial intelligence (213)
Autoimmune disease (32)
Automation (9)
Bankruptcy (178)
Best Places to Work (5564)
BIOSECURE Act (13)
Biosimilars (131)
Biotechnology (59)
Bladder cancer (57)
Brain cancer (26)
Breast cancer (175)
Cancer (1669)
Cardiovascular disease (183)
Career advice (729)
Career pathing (21)
CAR-T (74)
CDC (13)
Cell therapy (198)
Cervical cancer (9)
Clinical research (43764)
Collaboration (716)
Compensation (279)
Complete response letters (40)
COVID-19 (1156)
CRISPR (42)
C-suite (332)
Cystic fibrosis (74)
Data (2087)
Decentralized trials (2)
Denatured (23)
Depression (55)
Diabetes (206)
Diagnostics (1859)
Digital health (11)
Diversity (8)
Diversity, equity & inclusion (22)
Drug discovery (122)
Drug pricing (152)
Drug shortages (33)
Duchenne muscular dystrophy (109)
Earnings (40191)
Editorial (37)
Employer branding (10)
Employer resources (77)
Events (49843)
Executive appointments (581)
FDA (8927)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (3)
Frontotemporal dementia (2)
Funding (482)
Gene editing (74)
Generative AI (20)
Gene therapy (209)
GLP-1 (721)
Government (1973)
Grass and pollen (4)
Guidances (176)
Healthcare (5935)
HIV (21)
Huntington's disease (17)
IgA nephropathy (39)
Immunology and inflammation (137)
Immuno-oncology (12)
Indications (35)
Infectious disease (1258)
Inflammatory bowel disease (100)
Inflation Reduction Act (11)
Influenza (32)
Intellectual property (99)
Interviews (118)
IPO (7416)
IRA (52)
Job creations (2444)
Job search strategy (653)
Kidney cancer (8)
Labor market (49)
Layoffs (327)
Leadership (22)
Legal (4148)
Liver cancer (34)
Longevity (6)
Lung cancer (259)
Lymphoma (145)
Machine learning (12)
Management (31)
Manufacturing (371)
MASH (79)
Medical device (1995)
Medtech (1998)
Mergers & acquisitions (11591)
Metabolic disorders (697)
Multiple sclerosis (77)
NASH (20)
Neurodegenerative disease (93)
Neuropsychiatric disorders (36)
Neuroscience (1244)
NextGen: Class of 2025 (2371)
Non-profit (920)
Now hiring (36)
Obesity (409)
Opinion (214)
Ovarian cancer (49)
Pain (113)
Pancreatic cancer (70)
Parkinson's disease (110)
Partnered (13)
Patents (223)
Patient recruitment (131)
Peanut (19)
People (34063)
Pharmaceutical (74)
Pharmacy benefit managers (26)
Phase I (13726)
Phase II (18485)
Phase III (14865)
Pipeline (1472)
Policy (200)
Postmarket research (1623)
Preclinical (4819)
Press Release (29)
Prostate cancer (100)
Psychedelics (23)
Radiopharmaceuticals (169)
Rare diseases (367)
Real estate (3195)
Recruiting (32)
Regulatory (13142)
Reports (25)
Research institute (830)
Resumes & cover letters (139)
Rett syndrome (3)
RNA editing (8)
RSV (35)
Schizophrenia (89)
Series A (86)
Series B (55)
Service/supplier (7)
Sickle cell disease (48)
Special edition (20)
Spinal muscular atrophy (113)
Sponsored (15)
Startups (2033)
State (2)
Stomach cancer (10)
Supply chain (66)
Tariffs (80)
The Weekly (69)
Vaccines (361)
Venture capital (45)
Weight loss (301)
Women's health (20)
Worklife (8)
Date
Today (54)
Last 7 days (250)
Last 30 days (1124)
Last 365 days (15699)
2025 (11572)
2024 (17675)
2023 (19646)
2022 (25916)
2021 (26710)
2020 (24908)
2019 (20108)
2018 (15625)
2017 (17288)
2016 (16223)
2015 (18812)
2014 (14804)
2013 (12562)
2012 (13488)
2011 (13824)
2010 (12741)
Location
Africa (415)
Alabama (33)
Alaska (1)
Arizona (78)
Arkansas (8)
Asia (25450)
Australia (3277)
California (3728)
Canada (1519)
China (539)
Colorado (146)
Connecticut (147)
Delaware (127)
Europe (52626)
Florida (654)
Georgia (83)
Hawaii (1)
Idaho (17)
Illinois (353)
India (33)
Indiana (235)
Iowa (3)
Japan (211)
Kansas (75)
Kentucky (24)
Louisiana (3)
Maine (4)
Maryland (500)
Massachusetts (3078)
Michigan (58)
Minnesota (196)
Mississippi (3)
Missouri (34)
Montana (11)
Nebraska (11)
Nevada (31)
New Hampshire (8)
New Jersey (1487)
New Mexico (21)
New York (1054)
North Carolina (647)
North Dakota (2)
Northern California (1623)
Ohio (105)
Oklahoma (7)
Oregon (22)
Pennsylvania (859)
Puerto Rico (16)
Rhode Island (23)
South America (613)
South Carolina (6)
Southern California (1573)
Tennessee (50)
Texas (512)
United States (14519)
Utah (79)
Virginia (137)
Washington D.C. (55)
Washington State (298)
West Virginia (1)
Wisconsin (34)
340,718 Results for "rocket pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Rocket Re-Ignites Phase II Trial After FDA Lifts Clinical Hold
In late May, a patient died after receiving Rocket Pharmaceuticals’ investigational gene therapy for Danon disease, spurring the hold. After lowering the dose and changing the regimen of immune modulators patients receive, the company has received FDA clearance for the trial to continue.
August 20, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Rocket Pharmaceuticals to Participate in Upcoming September 2025 Investor Conferences
August 29, 2025
·
5 min read
Podcast
COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN
HHS Secretary RFK Jr. removes the COVID-19 vaccine recommendation for healthy kids and pregnant women—the latest in a string of changes to vaccine policies; judge issues an order to halt HHS’ reorganization and mass layoff plans; Rocket Pharmaceuticals’ pivotal Danon disease trial is on hold after a patient death; and President Trump has named Mehmet Oz to spearhead his Most Favored Nation drug pricing policy.
May 28, 2025
·
2 min read
·
Heather McKenzie
Press Releases
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
August 8, 2025
·
13 min read
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
July 25, 2025
·
8 min read
Press Releases
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
August 20, 2025
·
9 min read
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
·
4 min read
·
Annalee Armstrong
Gene therapy
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
Acute systemic infection caused the patient to develop fatal capillary leak syndrome, highlighting the unpredictability of gene therapies and potentially challenging investment in the space, analysts say.
May 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
July 1, 2025
·
7 min read
1 of 34,072
Next